QIAGEN Further Expands Business Scope in Asia
New Hong Kong subsidiary creates regional hub and strengthens service capa-bilities to address new customer demands
VENLO, The Netherlands / HONG KONG, China, July 31, 2007 - QIAGEN N.V., the leading provider of sample and assay technologies for research in life sciences, ap-plied testing and molecular diagnostics today officially opened its new subsidiary in Hong Kong. The location will serve as the Company's hub for its further business ex-pansion in this region. QIAGEN is hereby strengthening its regional service capabili-ties and facilitates access to the full offering of the company's leading portfolio of sample and assay technologies throughout this region.
"Hong Kong is a focal point for science, healthcare and the fast developing market for biomedical research", said Dr. Frauke Ehlert, General Manager of QIAGEN China & Hong Kong. "Our new local team and infrastructure will allow us to increase our sup-port of our customers for our sample and assay technologies in research, pharmaceu-tical development, applied testing and molecular diagnostics."
QIAGEN's Hong Kong subsidiary is a further step to expand the Company's presence in the rapidly growing Asian markets. With growth rates of over 60% Asia today is the Company's fastest growing marketplace. QIAGEN's strategic expansion into the re-gion began in 2005. Today the Company maintains 12 Asian offices with approxi-mately 300 employees. Including the subsidiary in Japan, they contribute approxi-mately 15 per cent to the Company's overall net sales.
QIAGEN's business activities in Asia address in particular the growing demand for so-lutions in diagnostics and life science research. Demographic developments and the further growth of middle classes in many Asian countries are spurring the demand for diagnostic solutions and also catalyzing increased investments in science.
QIAGEN is the leading provider of state-of-the-art molecular diagnostic and testing so-lutions for infectious diseases. Asia is significantly investing in this area to protect from human and economic impacts. QIAGEN will also target the strong potential for HPV testing in Asia by providing its leading HPV testing solutions as well as new develop-ments to this region. Sixty percent of the world's cervical cancer patients reside in the Asia Pacific.
About QIAGEN Asia
QIAGEN Asia, headquartered in Shanghai, was established in 2006 as one of the company's regional organization. It today encompasses 12 locations in China, Korea, Malaysia, Singapore and Hong Kong, employing close to 300 employees. Products to customers in Taiwan, India, Thailand and Vietnam are sold via local distributors; Ja-pan is an own entity within the QIAGEN organisation. Last year, QIAGEN received the Frost & Sullivan Award for Competitive Strategy Leadership in recognition of the com-pany's strategic initiatives in the Asia Pacific molecular testing market. Asia is QIAGEN's fastest growing regional market.
QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such pre-analytical sample preparation and assay solutions in re-search for life sciences, applied testing and molecular diagnostics. QIAGEN has de-veloped a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and bio-technology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2.600 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. Further information about QIAGEN can be found at www.qiagen.com.
Dr. Thomas Theuringer
Dr. Frauke Ehler